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G.B. Shaw’s entreaty, ‘‘Stimulate the phagocytes,’’ found its perfect interlocutor in Carl Nathan. Nearly 40
years ago, Nathan discovered macrophages were activated via soluble mediators released from T-lympho-
cytes—later identified as interferon-g (IFN-g)—for killing microbial pathogens. This year’s Robert Koch Prize
celebrates a lasting legacy for innate immunity.Whether patrolling portals of entry, lining
submucosae, or residing deep within
parenchyma, macrophages are essential
for host defense against the outsideworld.
These cells represent one of the most
highly specialized lineages in all of meta-
zoan immunity, with their abundant fixed
tissue distribution and rapid chemotactic
motility to sites of infection. Encountering
their quarry, they deploy a rich phagocytic
and biochemical armamentarium virtually
unmatched for sustained killing activity
against a broad collection of intracellular
pathogens (Nathan, 1987). Little wonder,
then, that macrophages have remained
an object of awe, fascination, and intense
study for well over a century (see Figure 1).
Metchnikoff first recorded the marked
gustatory profile of primitive mesoderm in
his classic experiments on starfish larvae
and Daphnia as well as the ‘‘degenerative
action’’ of vertebratemacrophages toward
some of the most feared pathogens
known, includingMycobacterium tubercu-
losis and Bacillus anthracis (Metchnikoff,
1905). He went one step further by formu-
lating a hypothesis that embraced their
evolutionary design to eliminate infection
as part of the ‘‘cellular’’ theory of immunity
(Metchnikoff, 1905). This theory acted as
a ballast against the then-more-popular
notion of a preformed antibody template
championed by Erlich. Indeed, the latter
school dominated immunology for next
30 years as cell theory receded and finally
lapsed into abeyance.
It was revived in 1939 by Max Lurie, with
his observation that vaccinated guinea pigs
and rabbits responded to tuberculosis
infection via heightened mobilization of
mononuclear phagocytes to lesions har-
boring bacilli (Lurie, 1939). This echoed the
earlier sentiments of Metchnikoff—often
overlooked—that reinoculated animals dis-
played enhanced ‘‘ingesting’’ capacity oftheir explantedmacrophages (Metchnikoff,
1905). G.B Mackaness, working with the
Gram-positive bacterium Listeria monocy-
togenes two decades later, arrived at
much the same conclusion (Mackaness,
1962). What differed was his observation
that macrophages mounted an effective
response to subsequent challenge not
only by the same bacterium, but to unre-
lated bacteria, as well (Mackaness, 1962).
Remarkably, the ability to elicit such
broad-spectrum activity was later shown
to rely on transfer of sensitized lymphocytes
in vivo, but only if the recipient was also
challenged with the same sensitizing
antigen.Hence, phagocytic immunity,while
nonspecific in its execution, was specific in
its elicitation. He coined the term ‘‘acquired
cellular resistance’’ to connote the collabo-
ration between these two cell types and
attributed macrophages—abundant within
infectious granulomas—as the one respon-
sible for direct elimination of bacteria
(Mackaness, 1969).
Harvard Beginnings: Macrophage
Activation
Shortly afterMackaness publishedhis find-
ings on lymphocytes instructing macro-
phages to clear infection, Carl Nathan
began examining the basis of this intercel-
lular communication as a student at Har-
vard Medical School within John David’s
laboratory. Using supernatants of restimu-
lated lymphocytes originating from Myco-
bacterium bovis BCG-immunized guinea
pigs, Nathan witnessed a pronounced
increase inmacrophageadherence,uptake
of heat-killed M. tuberculosis, and espe-
cially 14C-labeled glucose oxidation—the
latter an early measure of respiratory burst
capacity—when these supernatants were
applied tomacrophagemonotypic cultures
(Nathan et al., 1971). Thus, the ‘‘macro-
phage-activating factor,’’ or MAF, wasCell Host & Microa soluble component secreted by antigen-
specific T cells.
Subsequent physicochemical analysis
found that semipurified MAF behaved like
aglycoprotein in its sensitivity toneuramin-
idase and eluted from Sephadex G-100
columns as 35,000–55,000 molecular
weight complex. Its buoyant density
differed from that of other potential activa-
tors, lymphotoxin (tumor necrosis factor-
b [TNF-b]), and macrophage/monocyte
chemotactic factor, but beyond this, its
true identity remained unknown. Impor-
tantly, the semipurified fraction retained
potent macrophage stimulatory activity
as measured via the oxidative burst in
a dose-dependent fashion (Nathan et al.,
1973).
At Yale: The Oxidative Burst
Production of an oxidative burst yielding
reactive oxygen intermediates (ROI)—
superoxide (O2
), hydrogen peroxide
(H2O2) and the hydroxyl radical (OH$),
among others—is a cardinal feature of
immunologically activated macrophages
and critical for host defense (Nathan and
Shiloh, 2000) (Figure 1). As an oncology
fellow at Yale School of Medicine, Nathan
worked together with Richard K. Root to
better decipher this complex process.
Here, he applied more sensitive assays to
measureH2O2synthesis that in turnoffered
a more robust quantitative view of macro-
phage activation (Nathan and Root, 1977).
To his surprise, he found that peritoneally
elicited macrophages produced as much
phobol myristate acetate (PMA)-triggered
H2O2 as neutrophils, which were long re-
garded the most copious cellular source
of this bactericidal compound. And, like
his experiments at Harvard, those at Yale
reaffirmed the importance of preactivation.
Prior BCG, Cryptosporidium parvum, or
casein injection all facilitated the burstbe 5, May 21, 2009 ª2009 Elsevier Inc. 405
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Some landmark discoveries during the period beginning from the late 19th century through to the end of the 20th century are shown. Specific contributions made
by Carl Nathan depicted in orange.response of explanted macrophages
(Nathan and Root, 1977).
Rockefeller Years:
IFN-g Dependency
Armed now with a formidable assay and
a conviction that dissecting the process
of macrophage activation could provide
lasting insights into combating infection
and tumors, Nathan joined the Laboratory
of Cellular Physiology and Immunology at
Rockefeller University headed by Zanvil
Cohn, then the doyen ofmacrophage biol-
ogists. Surrounded by an eclectic and
influential group of colleagues, his scien-
tific approach broadened as he sought to
find the identity of MAF.
In 1983, he was rewarded for his perspi-
cacity. Using first conditioned media from
antigen—or mitogen-stimulated T cells,
and then partially purified lymphocyte-
derived IFN-g, Nathan made tentative
steps in uncovering MAF’s true nature.
When he applied pure IFN-g isolated
frombacteria expressing the newly cloned
human IFNGgene, togetherwith a neutral-
izing monoclonal antibody developed
against this cytokine, he resolved the issue
once and for all (Nathan et al., 1983). IFN-g
operates as an35 kDa dimer in solution,
fitting the earlier gel filtration estimates of
the fractions harboring MAF activity ob-
tained while at Harvard (Nathan et al.,
1973). At Rockefeller he showed that
IFN-g singly enhanced H2O2 release from406 Cell Host & Microbe 5, May 21, 2009 ª2human macrophages and stimulated their
ability to kill an intracellularmicrobial path-
ogen—in this case, Toxoplasma gondii
(Nathan et al., 1983).
Furthermore, IFN-g did it better—in
some cases over 100,000-fold on an equi-
molar basis—than other macrophage-
activating or T cell derived cytokines:
IFN-a, IFN-b, TNF, migration-inhibitory
factor (MIF), colony-stimulating factor
(CSF), colony-stimulating factor for granu-
locytes and macrophages (GM-CSF),
pluripotent CSF (pCSF), and interleukin-2
(IL-2) (Nathan et al., 1984). Today, IFN-g
still remains the most potent host-derived
stimulus for activating the macrophage
oxidativeburst andcontrolling intracellular
infection. This potency extends to the clin-
ical setting, as well, as Nathan soon
showed in studies on lepromatous leprosy
patients treated intradermally with the re-
combinant cytokine (Nathan et al., 1986).
Cornell Sojourn: Nitric Oxide and
Tuberculosis
After 9 years on the Rockefeller faculty,
Nathan moved across 68th Street in 1985
to become Stanton Griffiths Distinguished
ProfessorofMedicineatCornell University
Medical College (now Weill Cornell) and
then Director of the Tri-Institutional
M.D.-Ph.D. program encompassing Cor-
nell, Rockefeller, and the Sloan-Kettering
Institute. Indeed, the marriage of basic
biology with clinical research seemed009 Elsevier Inc.tailor made for his next experimental
sojourn: the role of nitric oxide ($NO) in
macrophage-mediated host defense.
Spurred on by a series of prescient
observations at MIT that macrophages
from BCG-infected and lipopolysaccha-
ride (LPS)-challenged mice secreted
abundant nitrite (NO2
) plus nitrate
(NO3
), Nathan set about characterizing
the enzyme(s) responsible for their biosyn-
thesis (reviewed in MacMicking et al.,
1997). He reasoned that NO2
 + NO3

represented end-oxidation products
stabilized under the aerobic conditions
employed during cell culture, and that a
reduced form, nitric oxide ($NO), was the
real cytotoxic intermediate. This opened
up the exciting possibility of activated
macrophages expressing a completely
different enzyme system to the phagocyte
oxidase studied earlier, one generating
reactive oxides of nitrogen instead of ROI
to combat infection (MacMicking et al.,
1997; Nathan and Shiloh, 2000).
What followed was a cavalcade of
discovery, propelling Nathan to one of
the most highly cited researchers during
the decade, 1990–2000, as the $NO field
permeated every corner of biology
and medicine (http://www.in-cites.com/
scientists/dr-carl-nathan.html). In brief,
he and his colleagues—notably, Dennis
Stuehr and Qiao-wen Xie—were among
the first to identify $NOas themacrophage
cytotoxin, purify and clone inducible nitric
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LPS-stimulatedmacrophages, and isolate
the components needed for its activity:
tetrahydrobiopterin, NADPH, O2, FAD,
FMN, heme, and calmodulin. This led to
a model whereby 17 binding reactions
help assemble a 300 kDa flavoenzyme to
generate a 30 Da diatomic gas—to date
the smallest molecule catalyzed in
a bond-forming process for export by
living cells (MacMicking et al., 1997).
A requirement for interferon-regulatory
factor-1 (IRF-1) and NF-kB in iNOS
expression was also deduced as prelude
to its action during host defense.
Examining the latter via chemical,
genetic, and cellular approaches, along
with the generation of iNOS-deficient
mice, Nathan and his colleagues provided
unequivocal evidence for the high-output
$NOpathwayexertingcontrol overbacteria
(Mycobacterium tuberculosis, L. monocy-
togenes, S. typhimurium), viruses (HSV-1,
vaccinia, ectromelia), and protozoa (Leish-
maniamajor,Toxoplasmagondii) (reviewed
inMacMickingetal., 1997;NathanandShi-
loh, 2000). Such studies represented just
the tip of an iceberg, however, as other
groups soon expanded the list of microbial
targets and implicated $NO in cytokine
regulation, T cell suppression, B cell differ-
entiation, and basophilic as well as mast
cell degranulation. That such a diffuse and
fleeting reactant like $NO could achieve
so much defied accepted norms of an
immune system built on the tenets of
receptor recognition. Equally startling was
the realization that most nucleated cells
could, when called upon, mount some
form of innate defense through production
of a quintessentially nonspecific gas, again
flouting conventionalwisdom (MacMicking
et al., 1997).
Such revelations extended across the
aisle to pathogens, as well. Any immune
molecule so ubiquitously deployed meant
most pathogens would have little alterna-
tive but to find ways to resist it. Probing
Mycobacterium tuberculosis and Salmo-
nella typhimurium, Nathan uncovered
a variety of sophisticated microbial detox-
ification and repair systems in place tocounter $NO and its congeners (Nathan
and Shiloh, 2000; Nathan, 2009). For M.
tuberculosis in particular, it provided ready
explanation for an ability to persist within
the human host despite the presence of
robust immunity. $NO exhibits a molar
potency comparable to the current antibi-
otics used to treat TB, underscoring the
importance of such detoxification path-
ways for M. tuberculosis that have been
acquired over centuries of coevolution.
Understanding this relationship—one of
Nathan’s most passionate concerns—
has serious implications for confronting
the current TB pandemic (Nathan, 2009).
A Life-long Legacy
Longbeforeweknew theexistenceof Toll-
like receptors (TLRs) or that LPS acted as
a ligand, Nathan had been studying this
and other macrophage-activating factors
intensively. He understood their influence
and was one of the first to demonstrate
theprofoundsynergismthatacombination
of host andmicrobial agonists can haveon
mobilizing macrophage function (Nathan,
1987). As a modern father of innate immu-
nity, he was ahead of his time.
In addition, Nathan gave considerable
attention to the process of macrophage
deactivation, tumor cell killing, and the
extraordinary plasticity of neutrophils in
response to cytokines like TNF-a and
matrix proteins. Such studies helped
bridge inflammation and immunity, all
during a period when T and B cells held
sway. Space limitations preclude detailing
the breadth and depth of these investiga-
tions, but their importance will undoubt-
edly emerge in the years to come (Nathan,
2006). It was for these reasons that the
Robert Koch Foundation, citing his
groundbreaking work on the ‘‘mecha-
nisms of antibacterial infection defense,’’
bestowed the leading international prize
in microbiology and infectious disease.
Hiswork on iNOS, in particular, galvanized
a whole generation of scientists, and dis-
solved disciplinary boundaries with its
open and flexible thinking about host
defense.Cell Host & MicroToday, Nathan continues to forge new
paths with an intellectual voracity and
scientific reach few can emulate. He
revels in nature’s complexity, providing
clarity for the rest of us. This trait, more
than any of the 60,000 citations his work
has garnered along the way, remains his
greatest legacy.
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